历届ASCO，AACR和ESMO肺癌领域大会发言汇总

 中国好声音The Voice of China

中国肺癌

ASCO大会发言 2008ASCO: Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer   于金明  山东省肿瘤医院

J.M. Yu

2008ASCO: Molecular imaging with 11C-PD153035 PET/CT to EGFR-TKI in advanced non-small cell lung cancer  于金明 山东省肿瘤医院

J.M. Yu

2011ASCO: Gefitinib versus placebo as maintenance therapy in patients withlocally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG0804): a multicentre, double-blind randomised phase 3 trial  张力 中山大学肿瘤防治中心

L. Zhang

2017ASCO: Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study   吴一龙 广东省人民医院

Y.L. Wu

2018ASCO:  Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050) : Final overall survival (OS) analysis   莫树锦（Tony Mok）香港中文大学

T.S.K. Mok

2020ASCO:  First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332)   王 晓珊  四川省人民医院

X.S. Wang

2020ASCO: Utilizing phenotypic characteristics of metastatic brain tumors to predict the probablity of circulating tumor DNA detection from cerebrospinal fluid   陈丽昆  中山大学肿瘤防治中心

L.K. Chen

2020ASCO:  CTONG1104: Adjuvant gefitinib verus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial   吴一龙 广东省人民医院

Y.L. Wu

2021ASCO:  CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjvant treatment of stage IIIA-N2 EGFR mutant non-small cell lung cancer   吴一龙 广东省人民医院

Y.L. Wu

2020ASCO:   Preliminary safety and efficacy results from phase I studies of DZD9008 in NSCLC patients with EGFR exon 20 insertion mtations  杨志新 台湾大学肿瘤医学研究所

Z.X. Yang

AACR大会发言 2018AACR: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: Results of the phase 3 Checkmate 078 study    吴一龙 广东省人民医院

Y.L. Wu

2019AACR: Preliminary efficacy and safety results of savolitinib treating patients with PSC and other NSCLC harboring MET exon 14 skipping mutations (NCT02897479)  陆舜  上海交通大学附属胸科医院

S. Lu

2019AACR:  Tumor-derived cell-free DNA from bronchoalveolar lavage fluid (BALF): A potential liquid biopsy analysis in lung cancer patients   张新  复旦大学附属中山医院

X. Zhang

2020AACR:  A phase I study of c-MET inhibitor bozitinib in patients with advanced NSCLC harboring c-MET alterations    吴一龙 广东省人民医院

Y.L. Wu

2020AACR: Almonertinib (HS-10296) for central nervous system metastases in pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer data from APOLLO study   陆舜  上海交通大学附属胸科医院

S. Lu

2020AACR:  Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicencer, two-stage, phase 2 trial   王洁   中国医学科学院肿瘤医院

J. Wang

2021AACR:  D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy：results from a phase II study   陆舜  上海交通大学附属胸科医院

S. Lu

2021AACR: A randomized， open-label, phase 3 study of sintilimab versus docetaxel in previously treated advaned/metastatic squamous non-small-cell lung cancer (sqNSCLC)     石远凯  中国医学科学院附属肿瘤医院

Y.K. Shi

2021AACR: Results from RATIONALE 303：A global Phase 3 study of Tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic NSCLC   周彩存  同济大学附属肺科医院

C.C. Zhou

ESMO大会发言 2010ESMO: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study 周彩存 同济大学附属肺科医院

C.C. Zhou

2012ESMO: Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, Fastact-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC)  莫树锦（Tony Mok）  香港中文大学

T.S.K. Mok

2014ESMO: Impact of harvested lymph nodes count on staging and survival at radical resection for non-small cell lung cancer: a minimum of 14 lymph nodes should be sampled  梁文华  广州医科大学附属第一医院

W.H. Liang

2014ESMO: EGFR mutation and survival outcomes in patients with completely resected lung adenocarcinoma-a multiple centers, non-interventional study (Ican Trial)  吴一龙 广东省人民医院

Y.L. Wu

2014ESMO:  Clinical value of circulating tumor cells in monitoring treatment response in Chinese patients with small cell lung cancer  程颖 吉林省肿瘤医院

Y. Cheng

2015ESMO: Recombinant human endostatin combined with chemotherapy for malignant pleural effusion  胡艳萍 湖北省肿瘤医院

Y.P. Hu

2016ESMO: Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvantchemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC final results of CSLC0501  吴一龙 广东省人民医院

Y.L. Wu

2016ESMO: First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC)  张力  中山大学肿瘤防治中心

L. Zhang

2018ESMO: CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study   钟文昭  广东省人民医院

W.Z. Zhong

2018ESMO:  Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth fact or receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)   吴一龙 广东省人民医院

Y.L. Wu

2018ESMO:  Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK+ advanced NSCLC   周彩存 同济大学附属肺科医院

C.C. Zhou

2019ESMO: Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)   程颖 吉林省肿瘤医院

Y. Cheng

2019ESMO: CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC  周清 广东省人民医院

Q. Zhou

2019ESMO:  Integrated genomic mutation and DNA methylation analyses of non-small cell lung cancer patients with brain metastases   范云  中国科学院大学附属医院（浙江省肿瘤医院）

Y.J. Xu

2020ESMO:  A phase 1b study of TQB2450 in combination with anlotinib in patients with advanced solid tumor    程颖  吉林省肿瘤医院

Y. Cheng

2020ESMO: ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): a multicenter, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)  张力  中山大学肿瘤防治中心

L. Zhang

2020ESMO: ORIENT-12: sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)    周彩存  同济大学附属肺科医院

C.C. Zhou

2020ESMO: MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)  杨云鹏  中山大学肿瘤防治中心

Y.P. Yang

2021ESMO:  DUBLIN-3 (BPI-2358-103): A global phase (Ph) 3 trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior Platinum-based regimen   韩宝惠  上海交通大学附属胸科医院

B.H. Han

2021ESMO: GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase 3 study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)  吴一龙 广东省人民医院

Y.L. Wu